{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T13:00:28Z","timestamp":1789390828057,"version":"build-2803163510"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,1,6]],"date-time":"2017-01-06T00:00:00Z","timestamp":1483660800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s00277-016-2915-4","type":"journal-article","created":{"date-parts":[[2017,1,6]],"date-time":"2017-01-06T01:26:25Z","timestamp":1483665985000},"page":"919-927","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Programmed cell death-1 pathway inhibition in myeloid malignancies: implications for myeloproliferative neoplasms"],"prefix":"10.1007","volume":"96","author":[{"given":"DC","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Iancu-Rubin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8400-0483","authenticated-orcid":false,"given":"J","family":"Mascarenhas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,1,6]]},"reference":[{"issue":"3","key":"2915_CR1","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1182\/blood-2006-12-064626","volume":"110","author":"SO Ciurea","year":"2007","unstructured":"Ciurea SO, Merchant D, Mahmud N, Ishii T, Zhao Y, Hu W et al (2007) Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood 110(3):986\u2013993","journal-title":"Blood"},{"issue":"20","key":"2915_CR2","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","volume":"127","author":"DA Arber","year":"2016","unstructured":"Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391\u20132405","journal-title":"Blood"},{"issue":"5","key":"2915_CR3","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646\u2013674","journal-title":"Cell"},{"issue":"7","key":"2915_CR4","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1084\/jem.192.7.1027","volume":"192","author":"GJ Freeman","year":"2000","unstructured":"Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H et al (2000) Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 192(7):1027\u20131034","journal-title":"J Exp Med"},{"issue":"1","key":"2915_CR5","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/j.immuni.2007.05.016","volume":"27","author":"MJ Butte","year":"2007","unstructured":"Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ (2007) Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27(1):111\u2013122","journal-title":"Immunity"},{"key":"2915_CR6","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpe AH (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677\u2013704","journal-title":"Annu Rev Immunol"},{"issue":"8","key":"2915_CR7","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong H, Strome SE, Salomao DR, Tamura H, Hirano F, Flies DB et al (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8(8):793\u2013800","journal-title":"Nat Med"},{"issue":"6","key":"2915_CR8","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/nri2326","volume":"8","author":"W Zou","year":"2008","unstructured":"Zou W, Chen L (2008) Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 8(6):467\u2013477","journal-title":"Nat Rev Immunol."},{"key":"2915_CR9","unstructured":"Administration USFaD (2014) FDA approves Keytruda for advanced melanoma"},{"key":"2915_CR10","unstructured":"Administration USFaD (2015) FDA approves Keytruda for advanced non-small cell lung cancer"},{"key":"2915_CR11","unstructured":"Administration USFaD (2014) FDA approves Opdivo for advanced melanoma"},{"key":"2915_CR12","unstructured":"Administration USFaD (2015) FDA expands approved use of Opdivo to treat lung cancer"},{"key":"2915_CR13","unstructured":"Administration USFaD (2015) Nivolumab (Opdivo) for Hodgkin lymphoma. 2016"},{"key":"2915_CR14","unstructured":"Administration USFaD (2015) FDA approves Opdivo to treat advanced form of kidney cancer"},{"key":"2915_CR15","unstructured":"Administration USFaD (2016) FDA approves Keytruda (pembrolizumab) for head and neck cancer"},{"issue":"3","key":"2915_CR16","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1158\/0008-5472.CAN-03-3259","volume":"64","author":"C Blank","year":"2004","unstructured":"Blank C, Brown I, Peterson AC, Spiotto M, Iwai Y, Honjo T et al (2004) PD-L1\/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res 64(3):1140\u20131145","journal-title":"Cancer Res"},{"issue":"26","key":"2915_CR17","doi-asserted-by":"publisher","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L et al (2015) Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 372(26):2521\u20132532","journal-title":"N Engl J Med"},{"issue":"21","key":"2915_CR18","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","volume":"372","author":"EB Garon","year":"2015","unstructured":"Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP et al (2015) Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 372(21):2018\u20132028","journal-title":"N Engl J Med"},{"issue":"1","key":"2915_CR19","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S1470-2045(13)70551-5","volume":"15","author":"JR Westin","year":"2014","unstructured":"Westin JR, Chu F, Zhang M, Fayad LE, Kwak LW, Fowler N et al (2014) Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial. Lancet Oncol 15(1):69\u201377","journal-title":"Lancet Oncol"},{"key":"2915_CR20","doi-asserted-by":"publisher","unstructured":"Armand P, Shipp MA, Ribrag V, Michot JM, Zinzani PL, Kuruvilla J, et al. (2016) Programmed death-1 blockade with pembrolizumab in patients with classical Hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol","DOI":"10.1200\/JCO.2016.67.3467"},{"issue":"4","key":"2915_CR21","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","volume":"372","author":"SM Ansell","year":"2015","unstructured":"Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M et al (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin\u2019s lymphoma. N Engl J Med 372(4):311\u2013319","journal-title":"N Engl J Med"},{"issue":"17","key":"2915_CR22","doi-asserted-by":"publisher","first-page":"3268","DOI":"10.1182\/blood-2010-05-282780","volume":"116","author":"MR Green","year":"2010","unstructured":"Green MR, Monti S, Rodig SJ, Juszczynski P, Currie T, O\u2019Donnell E et al (2010) Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma. Blood 116(17):3268\u20133277","journal-title":"Blood"},{"issue":"7","key":"2915_CR23","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1182\/blood-2009-12-255125","volume":"116","author":"A Kondo","year":"2010","unstructured":"Kondo A, Yamashita T, Tamura H, Zhao W, Tsuji T, Shimizu M et al (2010) Interferon-gamma and tumor necrosis factor-alpha induce an immunoinhibitory molecule, B7-H1, via nuclear factor-kappaB activation in blasts in myelodysplastic syndromes. Blood 116(7):1124\u20131131","journal-title":"Blood"},{"issue":"5","key":"2915_CR24","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1111\/j.1365-2141.2011.08683.x","volume":"153","author":"S Aggarwal","year":"2011","unstructured":"Aggarwal S, van de Loosdrecht AA, Alhan C, Ossenkoppele GJ, Westers TM, Bontkes HJ (2011) Role of immune responses in the pathogenesis of low-risk MDS and high-risk MDS: implications for immunotherapy. Br J Haematol 153(5):568\u2013581","journal-title":"Br J Haematol"},{"key":"2915_CR25","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1186\/s13045-015-0189-2","volume":"8","author":"FM Schnorfeil","year":"2015","unstructured":"Schnorfeil FM, Lichtenegger FS, Emmerig K, Schlueter M, Neitz JS, Draenert R et al (2015) T cells are functionally not impaired in AML: increased PD-1 expression is only seen at time of relapse and correlates with a shift towards the memory T cell compartment. J Hematol Oncol 8:93","journal-title":"J Hematol Oncol"},{"issue":"7","key":"2915_CR26","doi-asserted-by":"publisher","first-page":"828","DOI":"10.1038\/nm1609","volume":"13","author":"S Nagaraj","year":"2007","unstructured":"Nagaraj S, Gupta K, Pisarev V, Kinarsky L, Sherman S, Kang L et al (2007) Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 13(7):828\u2013835","journal-title":"Nat Med"},{"issue":"3","key":"2915_CR27","doi-asserted-by":"publisher","first-page":"e0116723","DOI":"10.1371\/journal.pone.0116723","volume":"10","author":"JC Wang","year":"2015","unstructured":"Wang JC, Sindhu H, Chen C, Kundra A, Kafeel MI, Wong C et al (2015) Immune derangements in patients with myelofibrosis: the role of Treg, Th17, and sIL2Ralpha. PLoS One 10(3):e0116723","journal-title":"PLoS One"},{"key":"2915_CR28","doi-asserted-by":"publisher","first-page":"e330","DOI":"10.1038\/bcj.2015.58","volume":"5","author":"Y Kong","year":"2015","unstructured":"Kong Y, Zhang J, Claxton DF, Ehmann WC, Rybka WB, Zhu L et al (2015) PD-1(hi)TIM-3(+) T cells associate with and predict leukemia relapse in AML patients post allogeneic stem cell transplantation. Blood Cancer J 5:e330","journal-title":"Blood Cancer J"},{"issue":"3","key":"2915_CR29","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1111\/ejh.12228","volume":"92","author":"H Kronig","year":"2014","unstructured":"Kronig H, Kremmler L, Haller B, Englert C, Peschel C, Andreesen R et al (2014) Interferon-induced programmed death-ligand 1 (PD-L1\/B7-H1) expression increases on human acute myeloid leukemia blast cells during treatment. Eur J Haematol 92(3):195\u2013203","journal-title":"Eur J Haematol"},{"issue":"15","key":"2915_CR30","doi-asserted-by":"publisher","first-page":"5111","DOI":"10.1158\/0008-5472.CAN-11-0108","volume":"71","author":"WJ Norde","year":"2011","unstructured":"Norde WJ, Maas F, Hobo W, Korman A, Quigley M, Kester MG et al (2011) PD-1\/PD-L1 interactions contribute to functional T-cell impairment in patients who relapse with cancer after allogeneic stem cell transplantation. Cancer Res 71(15):5111\u20135122","journal-title":"Cancer Res"},{"issue":"12","key":"2915_CR31","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1007\/s00262-010-0909-y","volume":"59","author":"C Berthon","year":"2010","unstructured":"Berthon C, Driss V, Liu J, Kuranda K, Leleu X, Jouy N et al (2010) In acute myeloid leukemia, B7-H1 (PD-L1) protection of blasts from cytotoxic T cells is induced by TLR ligands and interferon-gamma and can be reversed using MEK inhibitors. Cancer Immunol Immunother 59(12):1839\u20131849","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"2915_CR32","doi-asserted-by":"publisher","first-page":"4832","DOI":"10.4049\/jimmunol.181.7.4832","volume":"181","author":"KJ Oestreich","year":"2008","unstructured":"Oestreich KJ, Yoon H, Ahmed R, Boss JM (2008) NFATc1 regulates PD-1 expression upon T cell activation. J Immunol 181(7):4832\u20134839","journal-title":"J Immunol"},{"issue":"7","key":"2915_CR33","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1038\/ni.2046","volume":"12","author":"C Kao","year":"2011","unstructured":"Kao C, Oestreich KJ, Paley MA, Crawford A, Angelosanto JM, Ali MA et al (2011) Transcription factor T-bet represses expression of the inhibitory receptor PD-1 and sustains virus-specific CD8+ T cell responses during chronic infection. Nat Immunol 12(7):663\u2013671","journal-title":"Nat Immunol"},{"issue":"3","key":"2915_CR34","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1084\/jem.20130208","volume":"211","author":"P Lu","year":"2014","unstructured":"Lu P, Youngblood BA, Austin JW, Mohammed AU, Butler R, Ahmed R et al (2014) Blimp-1 represses CD8 T cell expression of PD-1 using a feed-forward transcriptional circuit during acute viral infection. J Exp Med 211(3):515\u2013527","journal-title":"J Exp Med"},{"issue":"6","key":"2915_CR35","doi-asserted-by":"publisher","first-page":"1280","DOI":"10.1038\/leu.2013.355","volume":"28","author":"H Yang","year":"2014","unstructured":"Yang H, Bueso-Ramos C, DiNardo C, Estecio MR, Davanlou M, Geng QR et al (2014) Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia 28(6):1280\u20131288","journal-title":"Leukemia"},{"key":"2915_CR36","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/asheducation-2013.1.511","volume":"2013","author":"Y Saunthararajah","year":"2013","unstructured":"Saunthararajah Y (2013) Key clinical observations after 5-azacytidine and decitabine treatment of myelodysplastic syndromes suggest practical solutions for better outcomes. Hematology Am Soc Hematol Educ Program 2013:511\u2013521","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"11","key":"2915_CR37","doi-asserted-by":"publisher","first-page":"9612","DOI":"10.18632\/oncotarget.3324","volume":"6","author":"AD Orskov","year":"2015","unstructured":"Orskov AD, Treppendahl MB, Skovbo A, Holm MS, Friis LS, Hokland M et al (2015) Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS\/AML patients: a rationale for combined targeting of PD-1 and DNA methylation. Oncotarget 6(11):9612\u20139626","journal-title":"Oncotarget"},{"key":"2915_CR38","doi-asserted-by":"publisher","first-page":"102476","DOI":"10.1155\/2015\/102476","volume":"2015","author":"HC Hasselbalch","year":"2015","unstructured":"Hasselbalch HC, Bjorn ME (2015) MPNs as inflammatory diseases: the evidence, consequences, and perspectives. Mediat Inflamm 2015:102476","journal-title":"Mediat Inflamm"},{"issue":"8","key":"2915_CR39","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1182\/blood-2011-03-340992","volume":"118","author":"CH Riley","year":"2011","unstructured":"Riley CH, Jensen MK, Brimnes MK, Hasselbalch HC, Bjerrum OW, Straten PT et al (2011) Increase in circulating CD4(+)CD25(+)Foxp3(+) T cells in patients with Philadelphia-negative chronic myeloproliferative neoplasms during treatment with IFN-alpha. Blood 118(8):2170\u20132173","journal-title":"Blood"},{"issue":"1","key":"2915_CR40","doi-asserted-by":"publisher","first-page":"e55818","DOI":"10.1371\/journal.pone.0055818","volume":"8","author":"L Christiansson","year":"2013","unstructured":"Christiansson L, Soderlund S, Svensson E, Mustjoki S, Bengtsson M, Simonsson B et al (2013) Increased level of myeloid-derived suppressor cells, programmed death receptor ligand 1\/programmed death receptor 1, and soluble CD25 in Sokal high risk chronic myeloid leukemia. PLoS One 8(1):e55818","journal-title":"PLoS One"},{"issue":"6","key":"2915_CR41","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1111\/bjh.13373","volume":"169","author":"S Parampalli Yajnanarayana","year":"2015","unstructured":"Parampalli Yajnanarayana S, Stubig T, Cornez I, Alchalby H, Schonberg K, Rudolph J et al (2015) JAK1\/2 inhibition impairs T cell function in vitro and in patients with myeloproliferative neoplasms. Br J Haematol 169(6):824\u2013833","journal-title":"Br J Haematol"},{"key":"2915_CR42","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3389\/fonc.2014.00349","volume":"4","author":"K De Veirman","year":"2014","unstructured":"De Veirman K, Van Valckenborgh E, Lahmar Q, Geeraerts X, De Bruyne E, Menu E et al (2014) Myeloid-derived suppressor cells as therapeutic target in hematological malignancies. Front Oncol 4:349","journal-title":"Front Oncol"},{"issue":"2","key":"2915_CR43","doi-asserted-by":"publisher","first-page":"e57114","DOI":"10.1371\/journal.pone.0057114","volume":"8","author":"B Zhang","year":"2013","unstructured":"Zhang B, Wang Z, Wu L, Zhang M, Li W, Ding J et al (2013) Circulating and tumor-infiltrating myeloid-derived suppressor cells in patients with colorectal carcinoma. PLoS One 8(2):e57114","journal-title":"PLoS One"},{"issue":"2","key":"2915_CR44","doi-asserted-by":"crossref","first-page":"1168","DOI":"10.18632\/oncotarget.6662","volume":"7","author":"L Pinton","year":"2016","unstructured":"Pinton L, Solito S, Damuzzo V, Francescato S, Pozzuoli A, Berizzi A et al (2016) Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression. Oncotarget 7(2):1168\u20131184","journal-title":"Oncotarget"},{"issue":"3","key":"2915_CR45","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/nri2506","volume":"9","author":"DI Gabrilovich","year":"2009","unstructured":"Gabrilovich DI, Nagaraj S (2009) Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9(3):162\u2013174","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"2915_CR46","doi-asserted-by":"publisher","first-page":"4595","DOI":"10.1172\/JCI67580","volume":"123","author":"X Chen","year":"2013","unstructured":"Chen X, Eksioglu EA, Zhou J, Zhang L, Djeu J, Fortenbery N et al (2013) Induction of myelodysplasia by myeloid-derived suppressor cells. J Clin Invest 123(11):4595\u20134611","journal-title":"J Clin Invest"},{"issue":"7","key":"2915_CR47","doi-asserted-by":"publisher","first-page":"e101848","DOI":"10.1371\/journal.pone.0101848","volume":"9","author":"C Giallongo","year":"2014","unstructured":"Giallongo C, Parrinello N, Tibullo D, La Cava P, Romano A, Chiarenza A et al (2014) Myeloid derived suppressor cells (MDSCs) are increased and exert immunosuppressive activity together with polymorphonuclear leukocytes (PMNs) in chronic myeloid leukemia patients. PLoS One 9(7):e101848","journal-title":"PLoS One"},{"issue":"5","key":"2915_CR48","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s12185-015-1865-2","volume":"102","author":"H Sun","year":"2015","unstructured":"Sun H, Li Y, Zhang ZF, Ju Y, Li L, Zhang BC et al (2015) Increase in myeloid-derived suppressor cells (MDSCs) associated with minimal residual disease (MRD) detection in adult acute myeloid leukemia. Int J Hematol 102(5):579\u2013586","journal-title":"Int J Hematol"},{"key":"2915_CR49","doi-asserted-by":"crossref","unstructured":"Kundra A, Baptiste S, Chen C, Sindhu H, Wang J-C. Programmed cell death receptor (PD-1), PD-1 ligand (PD-L1) expression and myeloid derived suppressor cells (MDSC) in myeloid neoplasms implicate the mechanism of IMiD treatment of myelofibrosis. Blood. 2013;122(21):2837-.","DOI":"10.1182\/blood.V122.21.2837.2837"},{"key":"2915_CR50","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.leukres.2016.02.004","volume":"43","author":"JC Wang","year":"2016","unstructured":"Wang JC, Kundra A, Andrei M, Baptiste S, Chen C, Wong C et al (2016) Myeloid-derived suppressor cells in patients with myeloproliferative neoplasm. Leuk Res 43:39\u201343","journal-title":"Leuk Res"},{"issue":"15","key":"2915_CR51","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1182\/blood-2014-09-600643","volume":"125","author":"F Mussai","year":"2015","unstructured":"Mussai F, Egan S, Higginbotham-Jones J, Perry T, Beggs A, Odintsova E et al (2015) Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target. Blood 125(15):2386\u20132396","journal-title":"Blood"},{"issue":"3","key":"2915_CR52","doi-asserted-by":"publisher","first-page":"e982382","DOI":"10.4161\/2162402X.2014.982382","volume":"4","author":"I Chevolet","year":"2015","unstructured":"Chevolet I, Speeckaert R, Schreuer M, Neyns B, Krysko O, Bachert C et al (2015) Characterization of the in vivo immune network of IDO, tryptophan metabolism, PD-L1, and CTLA-4 in circulating immune cells in melanoma. Oncoimmunology. 4(3):e982382","journal-title":"Oncoimmunology."},{"issue":"12","key":"2915_CR53","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.3109\/10428194.2014.904511","volume":"55","author":"J Favaloro","year":"2014","unstructured":"Favaloro J, Liyadipitiya T, Brown R, Yang S, Suen H, Woodland N et al (2014) Myeloid derived suppressor cells are numerically, functionally and phenotypically different in patients with multiple myeloma. Leuk Lymphoma 55(12):2893\u20132900","journal-title":"Leuk Lymphoma"},{"issue":"20","key":"2915_CR54","doi-asserted-by":"publisher","first-page":"4607","DOI":"10.1158\/1078-0432.CCR-15-0200","volume":"21","author":"G Gorgun","year":"2015","unstructured":"Gorgun G, Samur MK, Cowens KB, Paula S, Bianchi G, Anderson JE et al (2015) Lenalidomide enhances immune checkpoint blockade-induced immune response in multiple myeloma. Clin Cancer Res 21(20):4607\u20134618","journal-title":"Clin Cancer Res"},{"issue":"14","key":"2915_CR55","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1182\/blood-2010-03-275446","volume":"116","author":"Q Zhou","year":"2010","unstructured":"Zhou Q, Munger ME, Highfill SL, Tolar J, Weigel BJ, Riddle M et al (2010) Program death-1 signaling and regulatory T cells collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes in advanced acute myeloid leukemia. Blood 116(14):2484\u20132493","journal-title":"Blood"},{"issue":"8","key":"2915_CR56","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.1182\/blood-2008-09-179697","volume":"114","author":"S Mumprecht","year":"2009","unstructured":"Mumprecht S, Schurch C, Schwaller J, Solenthaler M, Ochsenbein AF (2009) Programmed death 1 signaling on chronic myeloid leukemia-specific T cells results in T-cell exhaustion and disease progression. Blood 114(8):1528\u20131536","journal-title":"Blood"},{"issue":"17","key":"2915_CR57","doi-asserted-by":"publisher","first-page":"4501","DOI":"10.1182\/blood-2010-10-310425","volume":"117","author":"Q Zhou","year":"2011","unstructured":"Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, Munn DH et al (2011) Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood 117(17):4501\u20134510","journal-title":"Blood"},{"issue":"5","key":"2915_CR58","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00262-016-1815-8","volume":"65","author":"SL Poh","year":"2016","unstructured":"Poh SL, Linn YC (2016) Immune checkpoint inhibitors enhance cytotoxicity of cytokine-induced killer cells against human myeloid leukaemic blasts. Cancer Immunol Immunother 65(5):525\u2013536","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"2915_CR59","doi-asserted-by":"publisher","first-page":"e1008824","DOI":"10.1080\/2162402X.2015.1008824","volume":"4","author":"R Bellucci","year":"2015","unstructured":"Bellucci R, Martin A, Bommarito D, Wang K, Hansen SH, Freeman GJ et al (2015) Interferon-gamma-induced activation of JAK1 and JAK2 suppresses tumor cell susceptibility to NK cells through upregulation of PD-L1 expression. Oncoimmunology 4(6):e1008824","journal-title":"Oncoimmunology"},{"issue":"11","key":"2915_CR60","doi-asserted-by":"publisher","first-page":"2187","DOI":"10.1158\/0008-5472.CAN-14-3198","volume":"75","author":"K Schonberg","year":"2015","unstructured":"Schonberg K, Rudolph J, Vonnahme M, Parampalli Yajnanarayana S, Cornez I, Hejazi M et al (2015) JAK inhibition impairs NK cell function in myeloproliferative neoplasms. Cancer Res 75(11):2187\u20132199","journal-title":"Cancer Res"},{"key":"2915_CR61","doi-asserted-by":"publisher","unstructured":"Schmohl JU, Nuebling T, Wild J, Kroell T, Salih HR, Schmetzer H (2016) RANK-L expression on blasts in patients with acute myeloid leukemia is associated with survival, PD-1\/PD-1L expression has no impact. Eur J Haematol","DOI":"10.1111\/ejh.12762"},{"key":"2915_CR62","unstructured":"Craig R, Tripp SR, Deininger M, Salama ME (2016) Programmed death ligand (PD-L1) expression is increased in spleens of myelofibrosis patients. United States and Canadian Academy ofy 2016 Annual Meeting. Seattle, Washington. Abstract 1353"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2915-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-016-2915-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2915-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,28]],"date-time":"2020-09-28T12:27:19Z","timestamp":1601296039000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-016-2915-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,6]]},"references-count":62,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["2915"],"URL":"https:\/\/doi.org\/10.1007\/s00277-016-2915-4","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.727180923.793564980","asserted-by":"object"}]},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,6]]}}}